Table 2 Treatment effects of ICS-containing regimens, LTRA, and tiotropium relative to AN-SABA on asthma symptoms, asthma-specific quality-of-life, and FEV1
Treatment | Asthma symptom score | AQLQ scoreb | % predicted FEV1b | |||||
|---|---|---|---|---|---|---|---|---|
| Â | Adults | Certainty | Adults | Certainty | Children | Certainty | Adults | Certainty |
AN-ICS | NA | NA | NA | NA | 1.91 (− 2.23,6.05) | Low | NA | NA |
Regular ICS |  − 0.33 (− 0.90,0.24) | Very low | 0.21 (0.07,0.35)* | Moderate | 4.12 (0.74,7.50)* | Very low | 3.53 (1.68,5.38)* | Low |
LTRA |  − 0.94 (− 1.93,0.04) | Low |  − 0.03 (− 0.19,0.13) | Moderate | 0.92 (− 5.65,7.49) | Very low |  − 0.20 (− 3.64,3.25) | Very low |
AN-ICS/FABA |  − 0.48 (− 1.49,0.54) | Low | NA | NA | NA | NA | 4.45 (1.76,7.15)* | Low |
Regular ICS/LABA |  − 0.41 (− 1.17,0.35) | Very low | 0.12 (− 0.04,0.28) | Moderate | 3.10** (− 8.32,14.52) | Very low | 3.45 (0.40,6.49)* | Low |
Tiotropium | NA | NA | NA | NA | NA | NA | NA | NA |